Abstract | BACKGROUND: OBJECTIVE: METHODS: Forty-nine patients with actinic keratosis were enrolled in this randomized comparative open-label study. Twenty-four patients applied 3% diclofenac gel once a daily to their lesions, while the other 25 patients were treated with a 5% imiquimod cream three times a week for 12 weeks. Patients were examined before treatment and every month of the treatment. Assessments were made by investigators according to the Investigator and the Patient Global Improvement Indices (IGII) and (PGII). RESULTS: According to the IGII results, a complete response was observed in 12% of the diclofenac group and 22% of the imiquimod group. For the PGII scores, a complete response was observed in 28% of the diclofenac group and 23% of the imiquimod group. There were no significant differences between the two groups (p > 0.05). Both treatments were well tolerated, with most adverse events related to skin. CONCLUSION: The two drugs were found to be equally effective and safe in the treatment of actinic keratosis but complete remission was very low. Therefore, topical treatments with these two drugs were not seen to be completely effective, and combined therapies and further studies are needed.
|
Authors | Osman Kose, Erol Koc, A Hakan Erbil, Ercan Caliskan, Zafer Kurumlu |
Journal | The Journal of dermatological treatment
(J Dermatolog Treat)
Vol. 19
Issue 3
Pg. 159-63
( 2008)
ISSN: 1471-1753 [Electronic] England |
PMID | 18569272
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adjuvants, Immunologic
- Aminoquinolines
- Anti-Inflammatory Agents, Non-Steroidal
- Gels
- Diclofenac
- Imiquimod
|
Topics |
- Adjuvants, Immunologic
(administration & dosage, adverse effects)
- Administration, Cutaneous
- Adult
- Aged
- Aged, 80 and over
- Aminoquinolines
(administration & dosage, adverse effects)
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage, adverse effects)
- Diclofenac
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Face
(pathology)
- Female
- Gels
- Humans
- Imiquimod
- Keratosis
(drug therapy, etiology, pathology)
- Male
- Middle Aged
- Severity of Illness Index
- Skin
(pathology)
- Treatment Outcome
- Ultraviolet Rays
(adverse effects)
|